Study finds hope for oral hepatitis C regimen

01/19/2012 | Bloomberg

A study published in the New England Journal of Medicine found that 36% of hepatitis C patients who took the oral drug candidates daclatasvir and asunaprevir had undetectable viral loads after 24 weeks. Meanwhile, nine in 10 patients responded to the combination plus ribavirin and interferon. This is the first study to indicate that difficult-to-treat cases might respond without the aid of injectable interferon, said the lead researcher.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID